LOWELL, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to ...

Rapid Micro Biosystems and Merck KGaA have signed a five-year global distribution agreement for Growth Direct systems and consumables. Rapid Micro Biosystems, Inc. has entered a five-year global ...

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism ...

The Company currently expects total revenue of between $6.2 million and $6.4 million in the fourth quarter of 2023, representing growth of approximately 45% compared to the prior-year period. The ...

Shares in Rapid Micro Biosystems jumped Friday in premarket trading after it said it signed an agreement with Merck's life science business to distribute its microbiology testing platform. Shares ...

Robert Spignesi, CEO, opened by highlighting third quarter revenue of $7.8 million, which was above the midpoint of guidance and marked the twelfth consecutive quarter meeting or beating revenue ...

The company reported Q1 2025 revenue of $7.2 million, reflecting a 28% increase compared to the previous year. Service revenue reached a quarterly record, growing 64% year-over-year. Gross margins ...

Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual ...